

World Journal of *Hepatology*

World J Hepatol 2020 December 27; 12(12): 1136-1371



MINIREVIEWS

- 1136** Spontaneous bacterial peritonitis due to carbapenemase-producing *Enterobacteriaceae*: Etiology and antibiotic treatment
Fiore M, Di Franco S, Alfieri A, Passavanti MB, Pace MC, Petrou S, Martora F, Leone S
- 1148** Molecular heterogeneity in intrahepatic cholangiocarcinoma
Ahn KS, Kang KJ
- 1158** Spectrum of esophageal motility disorders in patients with liver cirrhosis
Khalaf M, Castell D, Elias PS
- 1168** Metabolic associated fatty liver disease: Addressing a new era in liver transplantation
Gill MG, Majumdar A
- 1182** Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome — what we know so far
Anirvan P, Bharali P, Gogoi M, Thuluvath PJ, Singh SP, Satapathy SK

ORIGINAL ARTICLE

Basic Study

- 1198** Cyclin-dependent kinase inhibitors p21 and p27 function as critical regulators of liver regeneration following 90% hepatectomy in the rat
Moniaux N, Lacaze L, Gothland A, Deshayes A, Samuel D, Faivre J
- 1211** Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma
Atwa SM, Handoussa H, Hosny KM, Odenthal M, El Tayebi HM

Case Control Study

- 1228** Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population
Lee GH, Phyo WW, Loo WM, Kwok R, Ahmed T, Shabbir A, So J, Koh CJ, Hartono JL, Muthiah M, Lim K, Tan PS, Lee YM, Lim SG, Dan YY

Retrospective Cohort Study

- 1239** Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature
Campigotto M, Giuffrè M, Colombo A, Visintin A, Aversano A, Budel M, Masutti F, Abazia C, Crocé LS

Retrospective Study

- 1258** Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
Shafiq M, Walmann T, Nutalapati V, Gibson C, Zafar Y

- 1267** Timing of paracentesis and outcomes in hospitalized patients with decompensated cirrhosis
Tocia C, Dumitru A, Alexandrescu L, Popescu R, Dumitru E
- 1276** Bioelectrical impedance vector analysis evaluates cellularity and hydration in cirrhotic patients
Fernandes SA, Leonhardt LR, da Silva DM, Alves FD, Marroni CA
- 1289** Incidental biliary dilation in the era of the opiate epidemic: High prevalence of biliary dilation in opiate users evaluated in the Emergency Department
Barakat MT, Banerjee S

Clinical Trials Study

- 1299** Effect of non-alcoholic beer, diet and exercise on endothelial function, nutrition and quality of life in patients with cirrhosis
Macías-Rodríguez RU, Ruiz-Margáin A, Román-Calleja BM, Espin-Nasser ME, Flores-García NC, Torre A, Galicia-Hernández G, Rios-Torres SL, Fernández-del-Rivero G, Orea-Tejeda A, Lozano-Cruz OA

Observational Study

- 1314** HIPPOCRATES® project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting
Gaspar R, Liberal R, Tavares J, Morgado R, Macedo G

Prospective Study

- 1326** Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus
Brayette A, Essig M, Carrier P, Debette-Gratien M, Labrunie A, Alain S, Maynard M, Ganne-Carrié N, Nguyen-Khac E, Pinet P, De Ledinghen V, Renou C, Mathurin P, Vanlemmens C, Di Martino V, Gervais A, Foucher J, Isabelle FH, Vergniol J, Hourmand-Ollivier I, Cohen D, Duval X, Poinard T, Bardou M, Abergel A, Dao MT, Thévenot T, Hiriart JB, Canva V, Lassailly G, Aurières C, Boyer N, Thabut D, Bernard PH, Schnee M, Larrey D, Hanslik B, Hommel S, Jacques J, Loustaud-Ratti V

CASE REPORT

- 1341** Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports
Higley C, Hsu CC, Smith C, Nadella S, Lalos AT
- 1349** Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report
Yokoo H, Takahashi H, Hagiwara M, Iwata H, Imai K, Saito Y, Matsuno N, Furukawa H
- 1358** Hepatitis E virus re-infection accelerates hepatocellular carcinoma development and relapse in a patient with liver cirrhosis: A case report and review of literature
Lin XN, Lin QX, Li SM, Xie KP, Hou J, Chen R

LETTER TO THE EDITOR

- 1367** Autophagy related protein 9A increase in hepatitis B virus-associated hepatocellular carcinoma and the role in apoptosis
Kimkong I, Kunanopparat A

ABOUT COVER

Editor-in-Chief of *World Journal of Hepatology*, Dr. Nikolaos Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP, FACG, currently serves Professor of Medicine, Professor of Physiology, Pharmacology and Neuroscience, and Chief of Gastroenterology & Hepatology at New Jersey Medical School and the Medical Director of Liver Transplantation for University Hospital (United States). Dr. Pyrsopoulos is board certified in the areas of Internal Medicine, Gastroenterology and Transplant Hepatology. Dr. Pyrsopoulos is a Fellow of the American College of Physicians, American Gastroenterological Association, Royal College of Physicians at Edinburgh, and American Association of the Study of Liver Diseases. He is also a member of various medical associations, such as the European Association of the Study of the Liver, American Society of Gastrointestinal Endoscopy, and American Society of Transplantation, among others. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of *World Journal of Hepatology* (*WJH*, *World J Hepatol*) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Li-Li Wang; Production Department Director: Yun-Xiaojuan Wu; Editorial Office Director: Xiang Li.

NAME OF JOURNAL

World Journal of Hepatology

ISSN

ISSN 1948-5182 (online)

LAUNCH DATE

October 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Nikolaos Pyrsopoulos, Ke-Qin Hu, Koo Jeong Kang

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/1948-5182/editorialboard.htm>

PUBLICATION DATE

December 27, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Autophagy related protein 9A increase in hepatitis B virus-associated hepatocellular carcinoma and the role in apoptosis

Ingorn Kimkong, Areerat Kunanopparat

ORCID number: Ingorn Kimkong 0000-0002-8731-0356; Areerat Kunanopparat 0000-0001-6311-7255.

Author contributions: Kimkong I designed the research, wrote the manuscript and edited the manuscript; Kunanopparat A performed the majority of experiments and analyzed the data.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Specialty type: Gastroenterology and hepatology

Ingorn Kimkong, Department of Microbiology, Faculty of Science, Kasetsart University, Center for Advanced Studies in Tropical Natural Resources, National Research University – Kasetsart University, Bangkok 10900, Thailand

Areerat Kunanopparat, Department of Microbiology, Center of Excellence in Immunology and Immune Mediated Diseases, Chulalongkorn University, Bangkok 10330, Thailand

Corresponding author: Ingorn Kimkong, PhD, Associate Professor, Department of Microbiology, Faculty of Science, Kasetsart University, 50 Thanon Ngamwongwan, Lat Yao, Chatuchak, Bangkok 10900, Thailand. fsciiok@ku.ac.th

Abstract

The majority of hepatocellular carcinoma (HCC) cases are associated with the hepatitis B virus (HBV) infection. Autophagy related protein 9A (ATG9A) is a transmembrane protein required for autophagosome formation. In order to investigate the role of ATG9A in HBV-associated HCC, ATG9A protein expression was determined in tumor liver tissues and compared with adjacent nontumor tissues from HCC patients with or without HBV infection. In HBV-associated HCC tissues, ATG9A protein level was increased in tumor liver tissues, but not in cases of non-HBV HCC. Our findings suggested that ATG9A might be involved in HBV and cancer cell survival. Therefore, we aimed to analyze the function of ATG9A in HBV replication using RNA interference to evaluate the HBV DNA level using real-time PCR. In the present study, there were no significant differences between shATG9A-transfected HepG2.2.15 cells and the mock control. However, we found that silencing ATG9A affected apoptosis in HepG2.2.15 and HepG2 cell lines. Our results indicated that ATG9A might be partly involved in the survival of HCC. Thus, the inhibition of ATG9A together with other targets might be a potential drug target for HCC treatment.

Key Words: Autophagy; Hepatitis B virus; Hepatocellular carcinoma; Autophagy related protein 9A; Apoptosis; HBx

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Autophagy related protein 9A (ATG9A) protein expression was increased in

Country/Territory of origin:

Thailand

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

Received: July 31, 2020**Peer-review started:** July 31, 2020**First decision:** September 21, 2020**Revised:** September 29, 2020**Accepted:** October 19, 2020**Article in press:** October 19, 2020**Published online:** December 27, 2020**P-Reviewer:** Chung YH, Fan X**S-Editor:** Gao CC**L-Editor:** Filipodia**P-Editor:** Xing YX

tumor liver tissues compared to adjacent nontumor tissues from hepatocellular carcinoma (HCC) patients with hepatitis B virus infection. We showed that silencing ATG9A increased cell apoptosis of HepG2.2.15 and HepG2 cells. These results suggested that ATG9A protein is involved in the survival of HCC. The inhibition of ATG9A combined with other targets might be a potential drug target for HCC treatment.

Citation: Kimkong I, Kunanopparat A. Autophagy related protein 9A increase in hepatitis B virus-associated hepatocellular carcinoma and the role in apoptosis. *World J Hepatol* 2020; 12(12): 1367-1371

URL: <https://www.wjgnet.com/1948-5182/full/v12/i12/1367.htm>

DOI: <https://dx.doi.org/10.4254/wjh.v12.i12.1367>

TO THE EDITOR

Autophagy related protein 9A (ATG9A) is a transporter membrane molecule required for initial autophagosome formation in the autophagy pathway^[1]. ATG9A has been identified as having the function of a stimulator of interferon (IFN) genes (STING)inhibition. A loss of ATG9A results in enhanced assembly of STING/TANK-binding kinase 1 complexes in response to dsDNA, leading to an increase in innate immune responses^[2]. Silencing of ATG9A in macrophages increases STING-mediated IFN- β production and promotes cell viability^[3]. Our previous study reported that gene and protein expressions of ATG9A were upregulated in HepG2 and HepG2.2.15 cells compared with a THLE-2 hepatic cell line^[4]. Thus, in this study we investigated the role of ATG9A in hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) tissues. We found that ATG9A protein levels were highly increased in tumor liver tissues in HBV-associated HCC (9 of the 10 sample pairs). In the case of non-HBV HCC, ATG9A protein levels were decreased or slightly increased in tumor liver tissues (Figure 1). Therefore, we hypothesized that HBV induces the upregulation of ATG9A to benefit its replication. To determine the effect of ATG9A on HBV replication, HBV DNA was quantified from shATG9A-transfected cells and compared to mock cells. We observed no significant difference in shATG9A transfected cells (Figure 2).

HBV induces autophagy *via* the HBx protein and is directly involved in starvation-induced autophagy *via* upregulation of Beclin-1 expression^[5]. HBx also binds and activates phosphatidylinositol 3-kinase class III for autophagy induction^[6]. Our study showed that overexpression of HBx did not affect ATG9A expression (Figure 3), suggesting that the function of ATG9A may not involve HBV replication or viral clearance.

Autophagy is involved in tumor progression and tumor suppression. Several studies have shown that HBV induces autophagy for cell survival in an unsuitable environment^[7]. In order to search for the effect of ATG9A on apoptosis, we performed flow cytometry in HepG2.2.15 cells and compared against HepG2 cells after ATG9A silencing. We found that silencing ATG9A increased apoptosis in both cell lines (Figure 4), suggesting that ATG9A is involved in cell apoptosis related to HCC.

In conclusion, we provide information that ATG9A is highly expressed in HBV-associated HCC tissue samples and plays a role in cell apoptosis. Further studies are needed to investigate the mechanism of ATG9A-mediated inhibition of apoptosis in HCC.




Figure 1 Quantification of autophagy related protein 9A protein levels from hepatitis B virus-infected hepatocellular carcinoma patients and nonhepatitis B virus hepatocellular carcinoma patients. A: Western blotting with specific antibodies was used to analyze autophagy related protein 9A (ATG9A) protein expression in hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and nonHBV-HCC. Glyceraldehyde-3-phosphate dehydrogenase (GADPH) was used as a protein loading control; B: Graphs showing the intensity band ratio (tumor tissue/adjacent nontumor tissue) quantified using the LI-COR® image system for western blot analysis.




Figure 2 Silencing of autophagy related protein 9A by RNA interference and detection of hepatitis B virus DNA level. A: The western blot method was applied to analyze autophagy related protein 9 (ATG9A) protein levels against a mock treatment (control) and ATG9A knockdown (shATG9A) HepG2.2.15 cells; B: Quantitation of hepatitis B virus (HBV) DNA by real-time PCR. Total purified DNA from mock treatment (mock) and ATG9A knockdown (shATG9A) in HepG2.2.15 cells was amplified using preS1 specific primers. Hepatitis B virus preS1 plasmid was used as standard copy number. Data is shown as mean ± standard error of the four independent experiments. GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.




Figure 3 Quantitative real-time reverse transcriptase-PCR analysis of autophagy related protein 9A mRNA expression in HepG2-GFP and HepG2-HBx transfected cell lines. β -actin was used as an internal control. Data represent the mean \pm standard error in the three independent experiments. ATG9A: Autophagy related protein 9A.





Figure 4 Apoptosis assays of HepG2 and HepG2.2.15 transfected with sh-autophagy related protein 9A or shNeg (control). A: Cells were transiently transfected with shRNA plasmids for 72 h and then cultured in starvation medium for 4 h; B: Bar graphs showing the percentage of total apoptotic cells detected by Annexin V binding. Data represent the mean \pm standard error from the three independent experiments. ATG9A: Autophagy related protein 9A.

ACKNOWLEDGEMENTS

We are grateful to all the patients who participated in this study. We would like to thank Tangkijvanich P and Sirichindakul B for tissue biopsy collection and Hirankarn N for valuable advice.

REFERENCES

- 1 **Zhuang X**, Chung KP, Cui Y, Lin W, Gao C, Kang BH, Jiang L. ATG9 regulates autophagosome progression from the endoplasmic reticulum in Arabidopsis. *Proc Natl Acad Sci USA* 2017; **114**: E426-E435 [PMID: 28053229 DOI: 10.1073/pnas.1616299114]
- 2 **Saitoh T**, Fujita N, Hayashi T, Takahara K, Satoh T, Lee H, Matsunaga K, Kageyama S, Omori H, Noda T, Yamamoto N, Kawai T, Ishii K, Takeuchi O, Yoshimori T, Akira S. Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. *Proc Natl Acad Sci USA* 2009; **106**: 20842-20846 [PMID: 19926846 DOI: 10.1073/pnas.0911267106]
- 3 **Mitzel DN**, Lowry V, Shirali AC, Liu Y, Stout-Delgado HW. Age-enhanced endoplasmic reticulum stress contributes to increased Atg9A inhibition of STING-mediated IFN- β production during *Streptococcus pneumoniae* infection. *J Immunol* 2014; **192**: 4273-4283 [PMID: 24670807 DOI: 10.4049/jimmunol.1303090]
- 4 **Kunanopparat A**, Kimkong I, Palaga T, Tangkijvanich P, Sirichindakul B, Hirankarn N. Increased ATG5-ATG12 in hepatitis B virus-associated hepatocellular carcinoma and their role in apoptosis. *World J Gastroenterol* 2016; **22**: 8361-8374 [PMID: 27729742 DOI: 10.3748/wjg.v22.i37.8361]
- 5 **Tang H**, Da L, Mao Y, Li Y, Li D, Xu Z, Li F, Wang Y, Tiollais P, Li T, Zhao M. Hepatitis B virus X protein sensitizes cells to starvation-induced autophagy via up-regulation of beclin 1 expression. *Hepatology* 2009; **49**: 60-71 [PMID: 19065679 DOI: 10.1002/hep.22581]
- 6 **Sir D**, Tian Y, Chen WL, Ann DK, Yen TS, Ou JH. The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. *Proc Natl Acad Sci USA* 2010; **107**: 4383-4388 [PMID: 20142477 DOI: 10.1073/pnas.0911373107]
- 7 **Ávalos Y**, Canales J, Bravo-Sagua R, Criollo A, Lavandero S, Quest AF. Tumor suppression and promotion by autophagy. *Biomed Res Int* 2014; **2014**: 603980 [PMID: 25328887 DOI: 10.1155/2014/603980]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

